Boots POLITICAL

Corporate Structure & Primary Mission

Boots UK Limited (Companies House no. 00928555) was incorporated 11 March 1968, with its registered office in Nottingham, and operates under SIC codes 47190 (other retail sale in non-specialised stores) and 47730 (dispensing chemist in specialised stores) ¹. The company’s sole registered Person with Significant Control is Alliance Boots Holdings Limited (Companies House no. 04452715), notified 6 April 2016 as holding 75%+ of shares and voting rights ². Alliance Boots Holdings Limited’s own sole PSC is WBA Acquisitions UK Holdco 7 Limited, also notified 6 April 2016 ³. A direct, live re-fetch of Alliance Boots Holdings Limited’s PSC register on 30 October 2026 confirms this entry remains the sole active PSC, with “ownership of shares: 75% or more,” “ownership of voting rights: 75% or more,” and “right to appoint or remove directors,” and with no ceased PSCs and no ceased dates recorded - i.e., the entry has never been superseded or terminated on the official record ³. This fully confirms the existing audit’s statement and resolves the first examiner-directed question: the 2016-notified WBA Acquisitions UK Holdco 7 Limited PSC chain remains the officially registered control structure as of the research date, with no Companies House update reflecting the 2025 Sycamore take-private or the pending 2026 Wittington/Fairfax agreement. As corroborating context, WBA Acquisitions UK Holdco 7 Limited was independently located at Companies House company number 08155146 - formerly named AB Acquisitions UK Holdco 7 Limited from 24 July 2012 to 14 October 2016, a renaming consistent with Walgreens’ 31 December 2014 acquisition of the remainder of Alliance Boots and the group’s subsequent rebranding; this holding company’s own Companies House status is Active, incorporated 24 July 2012, registered office Sedley Place, 4th Floor, 361 Oxford Street, London W1C 2JL, SIC code 70100 (“Activities of head offices”) ⁴. Its own upstream PSC/ownership chain was not independently checked. Boots became part of Walgreens Boots Alliance, Inc. (WBA) on 31 December 2014 when Walgreens exercised its option to acquire the remainder of Alliance Boots ⁵. WBA’s FY2024 Exhibit 21 subsidiary list includes Boots UK Limited, Alliance Boots Holdings Limited, Boots Management Services Limited, The Boots Company PLC, Superior Holdings Limited, and WBA Acquisitions UK Topco Limited, all England & Wales entities ⁵. A separate FY2021 Exhibit 21 additionally listed Boots Opticians Professional Services Limited, whose continued presence in the FY2024 group structure could not be confirmed ⁶.

Under a Merger Agreement dated 6 March 2025, WBA was acquired by Blazing Star Parent, LLC, an affiliate of investment funds managed by Sycamore Partners Management, L.P., for $11.45 cash per share plus a contingent Divested Asset Proceeds right ⁷. The merger closed on or about 28 August 2025, with WBA stock delisted from Nasdaq and the company becoming privately held ^{8, 9, 10, 11, 12}. The second examiner-directed question - whether the deal’s headline value was ~$10 billion or ~$23.7 billion - is now resolved via primary SEC disclosure: a direct fetch of WBA’s own Form 8-K Exhibit 99.1 press release, filed in connection with the 6 March 2025 merger announcement, states verbatim that “the total value of the transaction represents up to $23.7 billion” ¹³. This figure comprises (a) $11.45 per share in cash paid to shareholders at closing, plus (b) a non-transferable “Divested Asset Proceed Right” (“DAP Right”) entitling shareholders to up to $3.00 per share in cash from future monetization of VillageMD-related interests (payment not guaranteed; aggregate maximum payout ≈ $2.7 billion), plus certain debt and other adjustments ^{13, 14}. No primary source supports a “$10 billion” transaction value; the only “$10 billion” figure identified in available searches refers to the size of Sycamore Partners’ investment fund as a firm, not the WBA deal price - a distinct figure that secondary coverage appears to have conflated with the transaction’s headline value ¹⁴. This corrects the existing audit’s prior unresolved discrepancy note: $23.7 billion is WBA’s own stated total transaction value, while the lower ~$10bn figures circulating in some secondary coverage (e.g. ^{9, 10}) likely reflect a cash-only or equity-value-only calculation excluding the DAP Right and assumed debt, though no source explicitly reconciled that specific sub-methodology.

Post-closing, WBA’s former portfolio - including Boots Group, Shields Health Solutions, CareCentrix, and VillageMD - was reported as being separated to operate independently of the Walgreens U.S. retail pharmacy business ⁹. The Boots Group was formally constituted on 28 August 2025 as the post-Sycamore-closing holding structure for Boots’ operations, per the Boots Group’s own Modern Slavery and Human Trafficking Statement ¹⁵, and this is corroborated by Boots Charitable Trust’s own FY2025 accounts, which state that on 28 August 2025, “The Boots Group Limited became the ultimate parent” following Sycamore’s completed acquisition of WBA, and that trustees assess this as not affecting the Trust’s operations or charitable objectives ¹⁶.

A further change-of-control transaction was announced 7–8 October 2026: Wittington Investments, Limited (the Weston family’s Canadian holding company) agreed to acquire The Boots Group from Sycamore Partners and the Pessina family for a total purchase price of approximately US$8.9 billion including assumed debt (variously reported as ~£6.7bn / ~C$12.7bn depending on currency conversion) ^{17, 18, 19, 20, 21, 22, 23}. Fairfax Financial Holdings Limited is partnering with Wittington, committing up to approximately US$2.3 billion of equity for a reported 50% equity stake, with Wittington retaining operational control ^{17, 18, 24}; the $2.3bn/50% figures rest on trade-press reporting (including a Canada-edition Insurance Business Magazine article quoting Fairfax CEO Prem Watsa and the Weston family directly) rather than an independently fetched Fairfax primary press release, but are corroborated across multiple outlets ^{17, 18, 24}. Per primary deal-counsel disclosures (Skadden, representing one side, and Davis Polk, representing The Boots Group), the acquisition covers Boots’ UK and Ireland retail and pharmacy operations, Boots Opticians, No7 Beauty Company, and Boots’ Thailand and franchise businesses, while Sycamore Partners and the Pessina family retain The Boots Group’s interests in Farmacias Benavides (Mexico) and Alliance Healthcare Deutschland (Germany) ^{22, 23}. Closing is expected in Q1 2027, subject to regulatory approvals and customary closing conditions; as of the research date (30 October 2026) the transaction has not closed ^{22, 23}. Search-snippet reporting states CIBC and Morgan Stanley are arranging acquisition debt financing, not independently verified via primary fetch ¹⁷. No public evidence identified of an updated Companies House PSC filing reflecting either Sycamore Partners’ or Wittington/Fairfax’s control of the Boots UK entity chain as of the research date, consistent with the fact that the Wittington/Fairfax deal remains unconsummated and the Alliance Boots Holdings Limited PSC register confirmed unchanged above ^{25, 2, 3}.

Executive & Leadership Footprint

Anthony Hemmerdinger became Managing Director of Boots UK and Ireland effective 4 November 2024, succeeding Seb James, having previously served as Boots’ retail & operations director since September 2022 and as COO of Asda from 2016–2022 ^{26, 27}. A direct fetch of Boots UK Limited’s current Companies House officers register (page 1 of 2) lists the company’s currently active statutory officers as Andrew Richard Thompson (Secretary, appointed 2 October 2015), Alexander David Baldock (Director, appointed 1 September 2026), Samuel James Hunter (Director, appointed 22 May 2023), and Jamie Kerruish (Director, appointed 17 September 2024), out of 55 officers listed historically ²⁵. Anthony Hemmerdinger was not confirmed as an active Companies House director on the register page retrieved; this is flagged as an unresolved discrepancy rather than a contradiction, since he may hold an executive (non-statutory) title, or appear on the unretrieved second page of the register ^{25, 28}. Alexander David Baldock’s 1 September 2026 appointment as a director is consistent with news reporting indicating Boots Group CEO Alex Baldock is expected to remain in post through the Wittington/Fairfax ownership transition ^{17, 25}.

At the former WBA group level, the FY2025 proxy statement (filed ~30 January 2025) listed twelve director nominees including Janice M. Babiak, Inderpal S. Bhandari, Ginger L. Graham (Lead Independent Director), Bryan C. Hanson, Robert L. Huffines, Valerie B. Jarrett, John A. Lederer, Stefano Pessina (Executive Chairman), Thomas E. Polen, Nancy M. Schlichting, William H. Shrank, and Timothy C. Wentworth (CEO) ²⁹. The proxy identifies Pessina as the “current designee” of the SP Investors under a Shareholders’ Agreement ²⁹. Stefano Pessina, as WBA’s Executive Chairman, was a Recused Director who did not participate in Board deliberations on the 2025 merger due to his conflicting interest as an SP Investor holding 16.8% voting power (145,621,079 shares) as of 3 June 2025 ⁷. Following closing, Schedule 13D/A Amendment No. 11 (dated 28 August 2025) confirms Pessina and Alliance Sante Participations Ltd. each reported 0 shares / 0% beneficial ownership, having “ceased to have beneficial ownership of any shares of Common Stock” ³⁰. Under a Reinvestment Agreement, Pessina and Alliance Sante Participations agreed to reinvest their aggregate cash merger consideration into new common equity of post-merger holding companies alongside Sycamore Partners, with Pessina “may serve on boards or governing bodies” of those entities ⁷; press reporting separately describes the Pessina family as having “rolled/reinvested 100% of their equity interests” into the new private structure without quantifying the resulting stake ^{9, 27}. Post-closing, Mike Motz (formerly of Staples US Retail, a Sycamore portfolio company) replaced Timothy Wentworth as CEO of the restructured Walgreens entity, and John A. Lederer, a senior advisor to Sycamore and former WBA director, was named Executive Chairman ^{9, 27}. No public evidence identified of Israel/Palestine-related ties for Motz or Lederer within available sources.

Regarding the incoming Boots ownership announced October 2026: Galen Weston, chairman of Wittington Investments, is reported - via trade-press sourcing including a direct quote-bearing article and corroborating multi-outlet coverage - to become Chairman of Boots upon completion ^{17, 24}; this was not independently located in either of the two law-firm transaction pages (Skadden, Davis Polk) fetched directly, which confirm Fairfax’s equity-partner role but do not name Weston ^{22, 23}, so the chairmanship detail rests on trade-press reporting rather than a primary deal document. A dedicated check of Galen Weston’s personal political, philanthropic, lobbying, or advocacy record (including any Israel/Palestine-related activity) was not completed: a Wikipedia biography fetch failed (incorrect URL/page not found), and no replacement search was completed within the available research budget - this remains an open item, not a “searched, none found” conclusion. Prem Watsa, Fairfax Financial’s Chairman and CEO, is quoted praising the Westons’ retail track record in connection with the deal ²⁴; a single direct search on Watsa for Israel-related donations, statements, or affiliations returned no Israel-related content, surfacing instead a 2020 ACLU letter urging Fairfax to divest from the for-profit bail industry (unrelated to Israel/Palestine) ³¹, the India-focused Fairfax India Charitable Foundation (founded 2016) ³², and Watsa’s Padma Shri (2020) and Order of Canada (2015) honours ^{33, 32}; this is a preliminary, single-query result rather than an exhaustive principal-level clearance, and no public evidence identified of Watsa having any Israel/Palestine-specific advocacy, donation, or board affiliation within the sources reviewed. Wittington Investments’ and George Weston Limited’s own Israel/Palestine exposure (sourcing, sponsorships, donations) was not searched in available research and remains an open gap.

New trustee-level governance activity within Boots Charitable Trust (reported under Internal Governance below) includes two further director departures in September 2025 - Preyash Thakrar and Lavinia Constance Lillian Moxley - identified via Companies House filing history; no reason for either departure, and no Israel/Palestine connection to either, was located within available research ³⁴.

Brand Heritage & State Partnerships

In May 2008, the Jewish Chronicle reported Boots was in negotiations to rebrand New Pharm - then Israel’s second-largest pharmacy chain, with 56 stores plus 30 concessions in Hamashbir Lazarchan department stores and 2007 sales of £131m - as “Boots Israel” via a franchise model stocking Boots own-label products ³⁵. New Pharm had no outlets of its own in Jerusalem or the West Bank at that time ³⁶. Boots’ on-record response to the Jewish Chronicle was: “We do not operate any pharmacy or wholesale activity at present in Israel and we do not comment on market speculation,” confirming no pharmacy/wholesale operations in Israel as of May 2008 but neither confirming nor denying the franchise negotiation ³⁵. A Boots sourcing delegation of roughly 10–11 people was reported scheduled for Tel Aviv in June 2008, organized with the Israeli embassy’s trade attaché and the Israel Export and International Co-operation Institute, with 25+ meetings confirmed and 60+ Israeli companies having applied to participate ³⁵. No evidence was located that the New Pharm “Boots Israel” rebrand was ever consummated, and no public evidence identified of any Boots retail footprint in Israel, past or present.

Operations in Occupied or Contested Territories

Boots previously stocked AHAVA Dead Sea Laboratories products, manufactured at a factory in Mitzpe Shalem, an Israeli settlement in the occupied West Bank on the Dead Sea’s western shore, built on land belonging to the Palestinian Bedouin village of ‘Ayn Trayba ^{36, 37}. The international community, and B’Tselem specifically, regard West Bank settlements and associated resource extraction as illegal under international law, a position Israel disputes ³⁷. A July 2008 BDS Movement call-to-action states that a customer-service enquiry to Boots found Boots “no longer stocks” AHAVA products, with no reason given ³⁶. This claim is in direct tension with the same-year Jewish Chronicle report that AHAVA “already supplies Boots” and was named as a confirmed supplier for the June 2008 Tel Aviv sourcing delegation ³⁵; both sources date to 2008, and no resolution of this contradiction was found. As industry-pattern context, Superdrug (UK) removed AHAVA from its third-party marketplace around 5 June 2026 after AFSC researchers supplied photos allegedly showing production activity and Dead Sea mud piles at the Mitzpe Shalem site dated 2025–2026; AHAVA denied operating a production facility at the site, stating that “by 2022, all production activities were consolidated within internationally recognised Israeli territory” ³⁸. That reporting does not mention Boots or any Boots response to the 2026 episode ³⁸. A Jewish News topic listing confirms this Superdrug/AHAVA article is dated 5 June 2026, 12:19pm, bylined Annabel Sinclair, summarized as Superdrug “blocks future sales of Israeli Dead Sea skincare brand following claims about activity at disputed site” ³⁹; Boots is not mentioned anywhere in connection with AHAVA on that page - the only Boots mention on the entire topic listing is an unrelated item about Huda Beauty being stocked at Selfridges, Harrods, Sephora, and Boots ³⁹. John Lewis (UK) had separately stopped stocking AHAVA in January 2011 following Palestine Solidarity Campaign publicity ³⁷. This marks a fourth consecutive research pass finding no evidence either confirming or disconfirming current Boots/AHAVA stocking status; Boots.com itself could not be successfully queried in any pass (blocked by a bot-check interstitial). Current Boots/AHAVA stocking status therefore remains unresolved. No public evidence identified of any Boots retail, pharmacy, wholesale, or franchise operations located within Israel or the occupied Palestinian territories at any point.

Lobbying, Advocacy, Financing & Logistics

A search of ProPublica’s Nonprofit Explorer for “Walgreens Boots Alliance Foundation” returned zero organization matches, indicating no U.S. IRS-990 filer under that name ⁴⁰. This is a search-scoped absence only; Stefano Pessina is Italian/Monegasque-domiciled, and no equivalent non-U.S. philanthropic-registry check was available. A targeted search for Stefano Pessina’s Israel-related donations, political contributions, foundation grants, or public statements on Israel/Palestine returned no results beyond generic biographical and business-profile content. A similarly targeted search for Timothy C. Wentworth (WBA CEO through the 2025 take-private) jointly with “Israel” returned no results. A search for WBA corporate PAC activity or lobbying on Israel-related policy returned no FEC.gov or Senate LDA database matches within available search snippets. With the October 2026 Wittington Investments/Fairfax Financial acquisition agreement, Prem Watsa (Fairfax’s Chairman/CEO) was separately checked for Israel-related ties, with no Israel-related content surfacing beyond an unrelated bail-industry divestment letter and an India-focused charitable foundation ^{31, 32}; Galen Weston, Wittington Investments, and George Weston Limited’s political, lobbying, and advocacy records were not searched and remain open items rather than confirmed absences. CIBC and Morgan Stanley are reported, via unverified search-snippet sourcing, to be arranging debt financing for the Wittington/Fairfax acquisition of Boots, a detail not independently confirmed via primary fetch ¹⁷. No public evidence identified of Boots-specific or WBA-specific lobbying, PAC spending, or financing activity tied to Israel/Palestine policy.

Internal Governance, Content & Retail Policies

No Boots UK-specific board of directors or governance structure, distinct from the WBA/Boots Group parent board, was located within earlier search results, though a subsequent direct Companies House officers-register fetch did identify the company’s current statutory directors and secretary (see Executive & Leadership Footprint) ^{28, 25}.

Boots Charitable Trust (registered charity 1045927, company 03039665) is described in Charity Commission register data as “a grant making Trust wholly funded by Boots UK Ltd,” registered 27 April 1995 with a broad charitable-purpose objects clause (“promote or support any purpose which is charitable” under English law), registered office 1 Thane Road West, Nottingham NG2 3AA ^{41, 42}. Direct attempts to fetch the Charity Commission’s own full-print register page have now returned an HTTP 403 block across four separate research passes ⁴³. A structured aggregator mirror (OpenCharities) of the Charity Commission’s register data confirms: for the year ended 31 August 2025, filed 8 June 2026 (Companies House filing history independently confirms the filing date as 6 June 2026 ³⁴), total income £553,029 and total expenditure £536,416, with net assets/funds of £56,476 and no employees ^{41, 42, 44}. Prior-year financial history per the same mirror: FY2024 income £491,023/expenditure £451,160 (filed 29 May 2025); FY2023 £271,026/£271,026; FY2022 £266,459/£266,459; FY2021 £266,834/£266,834; FY2020 £254,212/£267,775 ^{41, 42, 44}. Companies House’s own filing history for the Trust (company 03039665) independently corroborates these filing dates: accounts made up to 31 August 2025 filed 6 June 2026 (19 pages); accounts made up to 31 August 2024 filed 27 May 2025 (16 pages); accounts made up to 31 August 2023 filed 28 May 2024 (15 pages) ³⁴.

The FY2025 trustees’ annual report narrative has now been substantively retrieved via an OCR mirror of the filed accounts ¹⁶, resolving a gap flagged across prior research. Grant applications are assessed at regular board meetings “with particular regard to evidence of need and outreach”; the Trust favours projects with clearly defined benefits and reviews past-funded projects using charity feedback; the Charities Aid Foundation (CAF) administers applications and shortlists for trustees; there is no fixed maximum award, but grants are “generally £10,000 or less”; trustees met six times in the year ¹⁶. FY2025 (year to 31 August 2025) total grants were £483,387 across 52 awards (FY2024: £397,637), broken down as Health (18 awards, £167,553), Social care (23 awards, £211,634), Community development (9 awards, £85,026), and Lifelong learning (2 awards, £19,174) ¹⁶. Named grant recipients identified in the accounts (OCR quality, some names flagged as “garbled” by the fetch tool) include Nottingham Hospice, Changing Faces, and Oxfordshire Play Association, among others, described as “mostly small UK charities and community organisations” ¹⁶. Geographic scope per the FY2025 accounts was “Nottinghamshire and the wider UK” ¹⁶. Boots UK Limited, the Trust’s sole funder, provided £500,000 in FY2025 (FY2024: £437,500); net income FY2025 was £16,613; net funds carried forward were £56,476; trustees “expect funds to return to nil by 31 August 2026”; trustees received no remuneration ¹⁶. The FY2025 narrative contains no political-neutrality policy, no explicit restriction on (or reference to) international giving, and no mention of Israel, Palestine, or the Middle East anywhere in the retrieved/OCR’d text ¹⁶ - converting the prior audit’s “evidence gap” into a document-scoped absence finding, albeit one resting on an OCR-quality mirror rather than the Charity Commission’s own blocked PDF, so it should be treated as high-confidence but not fully certain.

Current trustees, confirmed via the OpenCharities mirror and corroborated by Companies House filing history, are Kyle John Rowe (Chair, appointed 3 November 2025), Adam Sebastian Wiles (appointed 3 November 2025), Beneeta Shah (appointed 22 November 2022), Jennifer Elizabeth Moffat (appointed 31 October 2023), Jenny Ann Rose (appointed 27 June 2025), Michael John Benford (appointed 31 October 2023), and Rebecca Louise Hitchings (appointed 27 June 2025), all unremunerated ^{41, 42, 44, 34}. Companies House filing history additionally identifies two further 2025 trustee departures not previously captured: termination of Preyash Thakrar as director, effective 5 September 2025 (filed 11 September 2025), and termination of Lavinia Constance Lillian Moxley as director, effective 24 September 2025 (filed 9 October 2025) ³⁴. No reason for either departure, and no Israel/Palestine connection to either, was located; the timing is consistent with ordinary trustee-board turnover coinciding with the Trust’s November 2025 chair/trustee refresh.

A live fetch of Boots-UK.com’s own “Boots Charitable Trust” page - distinct from, but describing the same policy as, the examiner-cited 9 December 2025 Giving Policy PDF - substantially fills the prior content gap on giving-policy detail ⁴⁵. It confirms funding areas of health, lifelong learning, community development, and social care, “with particular weight to projects that improve diversity, equality, and inclusion”; grants up to £10,000; and that, following a 2025 review, the Trust now focuses on Nottinghamshire (its home county) and “is not currently accepting applications for funding for projects supporting communities across the UK at this time,” with the next UK-wide application window stated to open 2 November 2026 ⁴⁵ - a narrower geographic scope than the FY2025 accounts describe, consistent with a mid-cycle policy tightening rather than a contradiction, since the accounts cover the year to 31 August 2025 while the page reflects the current (October 2026) live policy. Governance detail confirms the Trust is an “independent registered charity wholly funded by Boots UK Limited,” with applications reviewed quarterly by a board of seven trustees “all of whom hold senior roles at Boots or in legal services,” CAF running the online portal, and trustees permitted to interview applicants for up to 60 minutes ⁴⁵. Exclusions include funding for individuals, charities operating under 12 months, non-registered organisations with income above £5,000/year, charities that redistribute funds to others, projects with a statutory obligation, capital/construction projects, and projects whose ongoing maintenance would depend on Trust funding; product-donation requests are handled separately and not supported by the Trust or CAF ⁴⁵. No political or international-giving restriction, and no Israel/Palestine/Middle East content, appears on this page ⁴⁵. Combined with the FY2025 accounts narrative, two independent documents now converge on a picture of domestically (UK/Nottinghamshire) focused, generic-charitable giving with no identified political-neutrality clause and no conflict-region content either way. The 9 December 2025 Giving Policy PDF itself remains unextracted after two separate fetch attempts across research passes: the file downloads successfully as a 177.8KB binary, but its compressed FlateDecode text streams could not be decoded by available tooling; given the convergent content now available from the ESG page and the FY2025 accounts, this residual gap is lower-priority than previously assessed, but the PDF’s exact wording - which may differ from the paraphrased ESG page - remains formally unverified ⁴⁶.

On the Boots Group’s current (2025–2026) corporate policy suite - cited by the examiner as including a Supplier Code of Conduct, ESG policy statements, a Code of Conduct and Ethics, a Modern Slavery and Human Trafficking Statement, a “Modern Day Slavery – Subsidiaries 2025” document, a Restricted Substances List, and Impact/Technical Reports 2025 - a direct fetch of the Boots Group Modern Slavery and Human Trafficking Statement (covering FY ended 31 August 2025, last updated February 2026) confirms it references, but the fetch did not reproduce full text of, a separate Human Rights Policy Statement and Supplier Code of Conduct published on the corporate site; the statement itself opposes “forced or bonded labour, slavery, human trafficking, and harsh or inhumane treatment,” requires owned-brand suppliers to comply with the Code including via unannounced audits, lists “Convict/Indentured/Forced Labour” as a zero-tolerance issue, and reports zero zero-tolerance violations and over 300 ethical compliance assessments in FY2025 ¹⁵. Named compliance mechanisms include strengthened supplier screening under the US Uyghur Forced Labor Prevention Act, a cotton-supply-chain isotope-testing programme for geographic-origin verification, and reference to the EU Forced Labour Regulation, UK Modern Slavery Act 2015, California Transparency in Supply Chains Act, and Canada’s S-211 ¹⁵. The statement discloses operations across 11 countries (UK, Ireland, Thailand, Mexico, plus a German pharmaceutical-wholesale division) with 550+ approved owned-brand supplier sites across 40+ countries ¹⁵. The statement contains no mention of Israel, Palestine, occupied territories, conflict zones, or settlement-linked sourcing anywhere in its text - its human-rights/forced-labour framework is oriented toward Xinjiang/UFLPA-type risk categories, not Israel/Palestine ¹⁵. A companion “The Boots Group Modern Day Slavery – Subsidiaries 2025” PDF (file timestamp 26 January 2026) was fetched but was not machine-readable by available tooling, so its subsidiary-entity list could not be confirmed ⁴⁷. An earlier WBA-era “UK Entities Modern Slavery Statement” dated January 2024 was also identified by search but not independently fetched ⁴⁸. A direct fetch of The Boots Group’s own Environmental, Social & Governance landing page located working URLs for two previously-unlocated examiner-named documents - Impact Report 2025 ⁴⁹ and Technical Report 2025 ⁵⁰ - but neither PDF was opened within available research, so their content on human-rights, supply-chain, or Israel/Palestine-relevant provisions remains unconfirmed and is the single highest-value remaining lead ⁵¹. That same ESG page states the group “produces owned brand products while considering human and animal rights and expects suppliers to do the same,” references a “Sustainable Marketplace” pillar (“shared responsibility and collaboration”), and discloses “over 90% of palm oil used in Boots-owned brands is from RSPO physically certified sources”; no conflict-region or Israel/Palestine content appears on this page ⁵¹. The Supplier Code of Conduct, standalone Human Rights Policy Statement, Code of Conduct and Ethics, and Restricted Substances List are not mentioned or linked on this ESG landing page, and a dedicated site-wide search for these document titles on thebootsgroup.co.uk returned zero results from that domain, surfacing only unrelated companies’ documents instead ⁵¹. This suggests either these documents are not indexed by the search engine used, are hosted at an unguessed URL (e.g. under a “/latest-reports-and-resources” page, identified but not fetched), or do not exist as separate documents distinct from the Modern Slavery Statement and ESG page already reviewed - this remains an evidence gap, not a finding of absence ^{52, 51}.

As historical context, Personnel Today reported 15 June 2009 that Boots UK declined to renew its membership in the Ethical Trading Initiative (ETI), stating the ETI “only concentrates on labour standards” while Boots considered “sustainability more broadly”; ETI director Dan Rees called the move “deeply disappointed[ing],” and Boots said it was working with Business in the Community on an alternative framework ⁵³. Whether Boots ever rejoined the ETI or adopted a successor framework after 2009 is unconfirmed; the FY2025 Modern Slavery Statement makes no reference to ETI membership one way or the other ^{53, 15}. No public evidence identified of a Boots-specific retail stocking policy or governance document that addresses Israel/Palestine-related product sourcing specifically; the only sourcing-related record available remains the disputed 2008 AHAVA stocking episode addressed above.

Corporate Communications & Public Stance

Boots’ only on-record public statement bearing on Israel is its May 2008 response to the Jewish Chronicle: “We do not operate any pharmacy or wholesale activity at present in Israel and we do not comment on market speculation” ³⁵. No further corporate statement, press release, or public position from Boots or WBA regarding Israel, Palestine, the occupied territories, or the AHAVA sourcing controversy was identified in available sources. No public evidence identified of any Boots or WBA corporate communication addressing the 2008 BDS call-to-action or the 2026 AHAVA/Superdrug controversy. Regarding the October 2026 change-of-control announcement, public statements were limited to deal-related commentary: Fairfax Financial CEO Prem Watsa was quoted praising the Westons’ track record of having “grown and developed some of the most successful retail brands in Canada, including in pharmacy and beauty,” and a statement attributed to the Weston family called the deal “a meaningful opportunity to make a great business even better, through stable, long-term ownership” ²⁴; neither statement addresses Israel, Palestine, or human-rights/sourcing policy. WBA’s own 6 March 2025 press release announcing the Sycamore merger focuses exclusively on deal mechanics and transaction value and likewise contains no Israel/Palestine-related content ¹³.